Company intelligence / Profile preview

Xinda Biopharmaceuticals

Ownership: Private
Development stage: Other

Overview

Xinda Biopharmaceuticals is a leading Chinese biotech focused on monoclonal antibodies and metabolic disease therapeutics. Its most advanced asset, mazdutide—a dual GLP‑1/glucagon receptor agonist developed with Eli Lilly—has shown robust weight loss (~18.6%) in mid-stage trials and is now in multiple Phase 3 studies for obesity and type 2 diabetes. The company also develops biosimilars such as an ipilimumab biosimilar for oncology, currently in Phase 2 trials.

Therapeutic areas: DermatologyEndocrinologyOncology
Modalities: Monoclonal antibodyBiosimilarSmall moleculePeptide-based drug
Industry: Biotech

Partnerships

Eli Lilly (co-development of mazdutide)Innovent Biologics (collaboration on clinical programs)

Beyond the preview

Go deeper on Xinda Biopharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xinda Biopharmaceuticals.

Explore the full profile